TTR and amyloidosis: Recently, another study prepared NTLA-2001, an in vivo gene-editing therapeutic agent, made by lipid nanoparticles encapsulating messenger RNA of Cas9 protein and single guide RNA targeting misfolding transthyretin (TTR) responsible of transthyretin amyloidosis.